In a 71‑year‑old woman with a very high atypical P‑ANCA (perinuclear anti‑neutrophil cytoplasmic antibodies) titer, markedly elevated free κ and λ light chains, increased γ‑globulin and total globulin, what is the likely diagnosis and what diagnostic work‑up and initial treatment should be pursued?

Diagnostic Approach and Management

This patient requires urgent evaluation for ANCA-associated vasculitis (AAV), but the "atypical" P-ANCA pattern combined with polyclonal hypergammaglobulinemia and elevated free light chains suggests a broader differential that must include plasma cell dyscrasia, IgG4-related disease, and other systemic autoimmune conditions before committing to immunosuppressive therapy.

Understanding the Laboratory Pattern

The constellation of findings presents a diagnostic challenge:

• Atypical P-ANCA >1:640: While P-ANCA is classically associated with microscopic polyangiitis (MPA) and less commonly with granulomatosis with polyangiitis (GPA), the "atypical" designation is critical 1, 2. In vasculitis, P-ANCA typically recognizes myeloperoxidase (MPO) in 80-90% of cases, but atypical P-ANCA often targets other antigens including lactoferrin, elastase, cathepsin-G, or unknown antigens 2, 3.

• Elevated free kappa (78.7) and lambda (70.4) light chains: Both chains are elevated proportionally, suggesting polyclonal B-cell activation rather than monoclonal gammopathy 4, 5. However, in a 71-year-old with elevated globulins, plasma cell dyscrasia must be excluded 6.

• Elevated gamma globulin (2.2) and total globulin (4.3): This polyclonal hypergammaglobulinemia pattern occurs in chronic inflammation, autoimmune diseases, and IgG4-related disease 7, 5.

Critical Diagnostic Work-Up

Immediate Priority Testing

Confirm ANCA specificity with antigen-specific immunoassays for MPO and PR3 1, 8. The 2024 KDIGO and EULAR guidelines emphasize that high-quality antigen-specific assays (ELISA) are the preferred screening method 1, 8. If MPO or PR3 antibodies are positive, this strongly supports AAV; if negative despite high P-ANCA titer, consider alternative diagnoses 1, 2.

Exclude monoclonal gammopathy immediately 6:

• Serum protein electrophoresis (SPEP) with immunofixation
• Urine protein electrophoresis (UPEP) with immunofixation
• Calculate free light chain (FLC) kappa/lambda ratio (normal 0.26-1.65, or adjusted for renal function if eGFR <60) 9
• Even with polyclonal elevation, AL amyloidosis or light chain deposition disease can coexist 6

Assess for organ involvement 8:

• Urinalysis with microscopy (look for dysmorphic RBCs, RBC casts, proteinuria)
• Serum creatinine and eGFR
• Chest CT (not just X-ray) to detect pulmonary involvement, interstitial lung disease, or nodules 1
• Complete blood count, inflammatory markers (CRP, ESR)

Consider IgG4-related disease 7:

• Serum IgG4 level (elevated in IgG4-RD, which also shows polyclonal hypergammaglobulinemia and elevated free light chains)
• IgG subclass analysis

Secondary Evaluation

• Anti-GBM antibodies: Essential if pulmonary-renal syndrome is present 8
• ANA, anti-dsDNA, complement levels: To exclude systemic lupus erythematosus, which can present with P-ANCA and polyclonal hypergammaglobulinemia 2
• Rheumatoid factor, anti-CCP: Rheumatoid arthritis can have atypical P-ANCA 2
• Hepatitis B and C serology: Infections can cause P-ANCA and polyclonal activation 5

Tissue Diagnosis

If MPO or PR3-ANCA is positive with compatible clinical presentation, do not delay treatment for biopsy in rapidly deteriorating patients 8. The 2024 KDIGO guidelines state that in patients with clinical presentation compatible with small-vessel vasculitis and positive MPO/PR3-ANCA, immunosuppressive therapy should not be delayed, especially if rapidly progressive 8.

If ANCA specificity is negative or atypical, biopsy is mandatory 8:

• Kidney biopsy if renal involvement (look for pauci-immune crescentic glomerulonephritis vs. other patterns)
• Fat pad aspiration and bone marrow biopsy if suspecting amyloidosis 6
• Target organ biopsy based on clinical involvement

Treatment Algorithm

If MPO or PR3-ANCA Positive with Compatible Clinical Presentation

Initiate glucocorticoids plus rituximab or cyclophosphamide immediately 8. The 2024 KDIGO guidelines recommend this as first-line therapy (Grade 1B recommendation) 8.

Choice between rituximab vs. cyclophosphamide 8:

• Rituximab preferred: Relapsing disease, PR3-ANCA positivity, concerns about fertility or malignancy risk
• Cyclophosphamide preferred: Severe glomerulonephritis (creatinine >4 mg/dL), or consider combination of 2 IV pulses cyclophosphamide with rituximab 8

Glucocorticoid dosing (weight-based, rapid taper) 8:

• Week 1: 50-75 mg/day (based on weight)
• Taper to 5 mg/day by week 23-24 per PEXIVAS reduced-dose protocol 8

Refer to experienced AAV center immediately 8.

If ANCA Specificity Negative or Atypical Pattern

Do not initiate AAV-directed therapy without tissue diagnosis 1, 2. Atypical P-ANCA without MPO/PR3 specificity occurs in multiple conditions including inflammatory bowel disease, other autoimmune diseases, and infections where clinical significance is unclear 2, 3.

Pursue alternative diagnoses aggressively:

• If monoclonal protein identified: Hematology referral for plasma cell dyscrasia management
• If IgG4 elevated with compatible organ involvement: Consider IgG4-related disease (responds to glucocorticoids but different long-term management)
• If other autoimmune markers positive: Treat underlying condition

Critical Pitfalls to Avoid

Do not assume all P-ANCA represents vasculitis 2, 3. In a study of P-ANCA positive sera, only 50% of vasculitis patients had MPO specificity, while most other autoimmune diseases had unknown antigen targets 2.

Do not ignore the polyclonal light chain elevation 5. While this suggests polyclonal activation rather than myeloma, it can occur in IgG4-related disease, chronic inflammation, and autoimmune conditions 7, 5. The critical difference for serial FLC monitoring is 23-24%, so these elevations are significant 4.

Age matters for reference intervals 9. In patients over 70, especially with any degree of renal impairment, FLC reference ranges shift upward 9. Calculate eGFR and use appropriate reference intervals.

Do not delay treatment if true AAV with positive MPO/PR3-ANCA 8. Mortality risk is significant with pulmonary hemorrhage (10% of AAV patients) and rapidly progressive glomerulonephritis 8. However, equally do not treat empirically without confirming antigen specificity if the patient is stable enough for complete work-up 1, 2.